NCT01899755 - A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 10, 2013

Primary Completion Date

April 3, 2014

Study Completion Date

April 3, 2014

Conditions

Psoriasis

Interventions

DRUG

GSK2800528, solution for injection

Drug will be administered at 3 different dose levels by subcutaneous injection.

DRUG

Placebo (0.9% w/v Sodium Chloride), solution for injection

Subcutaneous injection of. 0.8 mL solution will be administered

DRUG

Adalimumab, solution for injection

Subcutaneous injection of 0.8 mL solution will be administered (40mg)

Trial Locations (1)

GSK Investigational Site, London